ReviewThe FEBS journal2025
Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting.
Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PDE4-Selective Inhibition in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Different Agents or Different Targets?Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cyclic AMP is a second messenger that is produced in response to the activation of many G-protein-coupled receptors. As each receptor type is linked to a transient but distinct physiological outcome, the activation of cAMP effector proteins is highly compartmentalized by the action of phosphodiesterases (PDEs). Phosphodiesterase type 4 (PDE4) enzymes are expressed as 25 different isoforms, and the function of each protein is linked to its cellular location(s). Fine-tuning of cAMP dynamics in space and time is underpinned by PDE4 activity shifts or PDE4 translocations that are driven by posttranslational modifications. As 'omics' technology improves, we are now learning more about these PDE4 events, and we can link them to diseases where aberrant cAMP signaling is causative. Additionally, recent advances allow us to pinpoint specific PDE4 modifications with targeted therapies that will lessen the chances of side effects. This review charts all known PDE4 modifications and links them to innovative existing pharmaceutical concepts or possible future therapeutic developments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.